TU
IONS icon

TDAM USA’s Ionis Pharmaceuticals IONS Stock Holding History

TDAM USA’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-4,068
Closed -$259K – 406
2015
Q1 		$259K Buy
4,068
+401
+11% +$27.2K 0.01% 369
2014
Q4 		$226K Buy
+3,667
New +$181K 0.01% 298

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

TDAM USA's IONS Position: Q2 2015 in Review

TDAM USA sold out of Ionis Pharmaceuticals (IONS) in Q2 2015, closing a stake of 4,068 shares — an estimated $259K sold.

TDAM USA first reported a position in IONS in Q4 2014 and held it in 2 quarters. The position peaked at $259K in Q1 2015. 353 funds tracked by Wall St. Rank hold IONS as of Q2 2015.

  • TDAM USA reported no remaining Ionis Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • TDAM USA sold 4,068 Ionis Pharmaceuticals shares in Q2 2015, an estimated $259K.
  • TDAM USA first reported a position in Ionis Pharmaceuticals in Q4 2014 and held it in 2 quarters.
  • TDAM USA's Ionis Pharmaceuticals position peaked at $259K in Q1 2015.
  • 353 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2015.

Based on TDAM USA's 13F filing for Q2 2015, filed 11 Aug 2015.